Merck KGaA bucks trend by edging away from CAR-T assets

21 December 2018
2019_biotech_test_vial_discovery_big

At a time when many big pharma companies are unreservedly buying into CAR-T therapies, Merck KGaA (MRK: DE) has taken a step away from the assets it has in the space.

The German company has amended the collaboration and license agreement it signed with Intrexon (NYSE: XON) in 2015 to develop and commercialize CAR-T therapies using Intrexon’s proprietary RheoSwitch Therapeutic System and the Sleeping Beauty non-viral gene integration technology.

Merck is now assigning development rights to Intrexon in return for shares of its common stock valued at $150 million, plus a note for another $25 million in stock.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology